AngioLab, Inc.
Founded in 1999, listed on KONEX in 2016, AngioLab develops new drugs and body-fat-reduction health functional foods.
As of 2026-10-08, AngioLab, Inc. has 9 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded on June 3, 1999 and listed on Korea's KONEX market on October 25, 2016, AngioLab, Inc. is a bio/new-drug company. Its business is centered on two lines: new drug development and body-fat-reduction health functional food products. It trades under ticker 251280 on KONEX and is classified in the bio/new-drug pharmaceutical category.
Clinical trials
data.go.kr4 MFDS clinical trial authorisations · 2015–2019 (Phase 2 2 · Phase 2a 2)
- Phase 2ALH-L1005정2019-12-24
3 trial sites
- Phase 2aSMZ1정2019-11-08
1 trial site
- Phase 2aSMZ1정2019-08-14
4 trial sites
- Phase 2SMZ1정2015-06-29
12 trial sites
Global clinical trials
ClinicalTrials.gov · sponsor-matchedPhase 2 · Completed · 2020-07 · NCT04503746
Phase 2 · Completed · 2019-12 · NCT04342793
Phase 2 · Completed · 2018-12 · NCT03725501
Publications
PubMed · affiliation-matched- Enhanced Upconversion Luminescent Nanocarrier for Effective Tumor-Targeted Photodynamic Therapy Combined with Immunotherapy.
Advanced healthcare materials · 2026-04 · Choi J, Yuh HS, Park BY 외 1
- Antiangiogenic Herbal Composition Ob-X Reduces Abdominal Visceral Fat in Humans: A Randomized, Double-Blind, Placebo-Controlled Study.
Evidence-based complementary and alternative medicine : eCAM · 2018-01 · Kang JH, Jeong IS, Kim MY
- Efficacy of horse chestnut leaf extract ALH-L1005 as a matrix metalloproteinase inhibitor in ligature-induced periodontitis in canine model.
Journal of veterinary science · 2017-06 · Kim SE, Kim TH, Park SA 외 6
- The anti-angiogenic herbal extract from Melissa officinalis inhibits adipogenesis in 3T3-L1 adipocytes and suppresses adipocyte hypertrophy in high fat diet-induced obese C57BL/6J mice.
Journal of ethnopharmacology · 2016-02 · Woo S, Yoon M, Kim J 외 4
- Reduction of Adipose Tissue Mass by the Angiogenesis Inhibitor ALS-L1023 from Melissa officinalis.
PloS one · 2015-01 · Park BY, Lee H, Woo S 외 10
- ALH-L1005 attenuates endotoxin induced inner ear damage.
International journal of pediatric otorhinolaryngology · 2014-03 · Jang CH, Cho YB, Choi CH 외 5
- The anti-angiogenic herbal composition Ob-X inhibits adipose tissue growth in obese mice.
International journal of obesity (2005) · 2010-05 · Kim MY, Park BY, Lee HS 외 8
- Inhibition of human cytochrome P450 3A4 activity by zinc(II) ion.
Toxicology letters · 2005-04 · Kim JS, Yun CH
- Differential effect of copper (II) on the cytochrome P450 enzymes and NADPH-cytochrome P450 reductase: inhibition of cytochrome P450-catalyzed reactions by copper (II) ion.
Biochemistry · 2002-07 · Kim JS, Ahn T, Yim SK 외 1
Patents
KIPRIS · applicant-matchedPublished · 2025-10 · Application 1020250147490
Registered · 2024-11 · Application 1020240158447
Published · 2024-09 · Application 1020240124205
US · Registered · 2023-10 · Application 18381023
CN · Published · 2022-08 · Application 202280058957.4
US · Published · 2022-08 · Application 18580366
EP · Published · 2022-08 · Application 22865037.0
PCT · Published · 2022-08 · Application PCT/KR2022/013018
Rejected · 2021-09 · Application 1020210116512
CN · Published · 2021-04 · Application 202180027089.9
Show 56 more patents
US · Published · 2021-04 · Application 17914455
EP · Registered · 2021-04 · Application 21785025.4
PCT · Published · 2021-04 · Application PCT/KR2021/004375
Registered · 2021-03 · Application 1020210032830
US · Registered · 2020-10 · Application 17084978
CN · Published · 2020-05 · Application 202080014383.1
US · Published · 2020-05 · Application 17427168
EP · Published · 2020-05 · Application 20810304.4
PCT · Published · 2020-05 · Application PCT/KR2020/006669
Registered · 2020-04 · Application 1020200042856
Registered · 2019-05 · Application 1020190060305
Rejected · 2018-12 · Application 1020207019980
Published · 2018-12 · Application 1020247039487
PCT · Published · 2018-12 · Application PCT/KR2018/016486
Registered · 2016-06 · Application 1020160079591
CN · Published · 2008-08 · Application 200880103608
EP · Registered · 2008-08 · Application 08793448.5
PCT · Published · 2008-08 · Application PCT/KR2008/004938
Rejected · 2008-04 · Application 1020080032859
PCT · Published · 2008-01 · Application PCT/KR2008/000412
Registered · 2007-08 · Application 1020070084929
Registered · 2007-01 · Application 1020070009082
CN · Published · 2006-10 · Application 200680036456
EP · Registered · 2006-10 · Application 06799129.9
EP · Registered · 2006-05 · Application 06757650.4
Expired · 2005-10 · Application 1020050093577
Expired · 2005-05 · Application 1020050038014
Expired · 2005-05 · Application 1020050038015
Expired · 2004-06 · Application 1020040041182
Expired · 2003-11 · Application 1020030077120
PCT · Published · 2003-03 · Application PCT/KR2003/000419
PCT · Published · 2003-01 · Application PCT/KR2003/000015
Rejected · 2002-12 · Application 1020020088329
EP · Registered · 2002-10 · Application 02802394.3
PCT · Published · 2002-10 · Application PCT/KR2002/002031
EP · Published · 2002-10 · Application 02788896.5
PCT · Published · 2002-10 · Application PCT/KR2002/002000
Expired · 2002-10 · Application 1020020063407
PCT · Published · 2002-04 · Application PCT/KR2002/000622
Expired · 2002-03 · Application 1020020011500
Expired · 2002-01 · Application 1020020001057
EP · Registered · 2001-12 · Application 01270341.9
PCT · Published · 2001-12 · Application PCT/KR2001/002148
Expired · 2001-12 · Application 1020010077392
Expired · 2001-11 · Application 1020010067950
PCT · Published · 2001-08 · Application PCT/KR2001/001325
PCT · Published · 2001-07 · Application PCT/KR2001/001280
PCT · Published · 2001-07 · Application PCT/KR2001/001281
Rejected · 2001-05 · Application 1020010027823
Expired · 2001-04 · Application 1020010018674
Expired · 2001-03 · Application 1020010011850
Expired · 2001-02 · Application 1020010008470
Registered · 2000-08 · Application 1020000045265
Rejected · 2000-07 · Application 1020000043589
Expired · 2000-07 · Application 1020000043454
Expired · 1997-03 · Application 1019970009387
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive1
- OpenAIOAI-SearchBot3
- PerplexityPerplexityBot3
- AnthropicClaudeBot2
- MicrosoftBingbot1
- GoogleGoogleOther1
Measured since Aug 27, 2026 · 5 AI engines · last read Oct 6, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for AngioLab, Inc. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.
Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.
KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition